Untreated tumor tissues showed a marked expression of NFκB, which was mainly allocated in the viable tumor cells, as shown in Figure 6A. Along with reduced viable tumor cells after cisplatin and/or α-hederin treatment, NFκB showed less expressional allocation throughout the residual EST tumor and its necrotic surrounds, as shown in Figure 6B,C. The gene discussed is NFKB1; the disease is neoplasm.